As Onyx Details Come Out, Amgen Turns To Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.
You may also be interested in...
Amgen Aims To Submit NDA for PCSK9 Candidate During “Data-Rich” 2014
The company now appears to be neck and neck with Regeneron in the race to market the first PCSK9 blocker for high cholesterol, with a filing possible by the end of the year. The drug is part of a deep late-stage pipeline, expected to yield pivotal data on numerous drugs by 2016.
Which Biosimilars Will Payers Cover? Manufacturer Pedigree Will Be A Factor
Large established firms will have an advantage in the competition for formulary position, payer survey finds.
Emerging Markets Earnings Roundup: Novartis, Amgen (Part 2)
Novartis executives trumpeted robust growth across most emerging markets, while cautioning a slowdown in China due to the industry-wide compliance probe. For Amgen, a play to expand internationally is said to be paying off though questions remain about its plans for Japan.